The Medical Affairs Blueprint for Biotech

A strategy to de-risk development, accelerate approval, and secure patient access

Medical affairs should be set up early as a core part of the strategy. Engaging late in the game can be a risky mistake.

The whitepaper lays out a practical “medical affairs blueprint” for pre-revenue and early-commercial biotechs to build medical affairs from a blank slate, treating it as a core strategic pillar from the outset rather than a late-stage support function. The authors suggest that where the company’s survival hinges on a single asset, delaying medical affairs is not just outdated but a material strategic liability. Instead, early medical affairs should act as a catalytic, integrative force that elevates value across approval, access, advocacy, and adoption from day one.